Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01840111 · ClinicalTrials.gov registry record · NA
Environments as Smoking Cues: Imaging Brain Substrates, Developing New Treatments (CameraCue)
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 67
- Enrollment target
NCT01840111: Completed NA study, sponsored by Duke University.
NCT01840111 is a NA study that has completed, run by Duke University. The registered enrollment target is 67 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01840111, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 67 participants
- Enrollment target
Study Summary
The overarching goals of this proposal are to 1) identify the network of brain regions specifically activated by personal smoking environment cues and 2) to evaluate the effects of exposure to these cues on smoke self-administration and subjective reactivity. The results of this study will inform the development of novel and more efficacious cue-exposures therapies targeted at helping smokers quit smoking and will provide novel mechanism information regarding the influence of environmental context on drug taking. The investigator hypothesizes that cue-exposure treatments (CETs), in which drug use is prevented during exposure to drug cues (e.g. lit cigarette) have been of limited efficacy in part because they have not included cues representative of the contexts in which drug use occurs. By demonstrating that context cues have a differential and robust influence on brain and behavioral responses, we will have provided a substantial basis for including such stimuli in the context of treatment. At the same time, we will have identified novel mechanisms by which such stimuli promote continued drug use and relapse.
Primary Outcome
During fMRI scanning participants will view pictures of personal and standard smoking and non-smoking environments; and also pictures of smoking-related and non-smoking related objects
Interventions
- BEHAVIORAL Quit Smoking 6 hours
- BEHAVIORAL Quit Smoking 24 hours
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-07 |
| Phase | NA |
What the finished NCT01840111 record still lists
NCT01840111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Quit Smoking 6 hours is the first listed.
NCT01840111 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01840111 about?
NCT01840111 is a clinical study titled "Environments as Smoking Cues: Imaging Brain Substrates, Developing New Treatments (CameraCue)". The overarching goals of this proposal are to 1) identify the network of brain regions specifically activated by personal smoking environment cues and 2) to evaluate the effects of exposure to these cues on smoke self-administration and subjective reactivity. The results of this study will inform th...
What is the current status of trial NCT01840111?
This trial is currently completed. It is a NA study. The enrollment target is 67 participants. The study started on 2012-12. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01840111?
The interventions under investigation include: Quit Smoking 6 hours (BEHAVIORAL), Quit Smoking 24 hours (BEHAVIORAL).
Who is sponsoring clinical trial NCT01840111?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01840111's enrollment target sits among peer trials
67 1139th of 2000 higher than 862 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia